Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Apr 28, 2015 at 8:00 AM EDT

Pfizer Dodges a Bullet on Earnings

Pfizer has reported better-than-expected first-quarter earnings and revenue and offered guidance.

Chris Lange | Apr 27, 2015 at 3:22 PM EDT

What to Expect From Merck and Pfizer Earnings

Pharmaceutical giants Merck and Pfizer are both releasing their first quarter financial results early Tuesday.

Chris Lange | Apr 27, 2015 at 1:25 PM EDT

Key Analyst Sees Nearly 30% Upside in Ironwood

Merrill Lynch brings another company to the forefront that it considers a buy. Ironwood Pharmaceuticals is viewed favorably by the…

Chris Lange | Apr 27, 2015 at 10:55 AM EDT

A Real Heartbreak for Celladon

Celladon announced negative results in clinical trial and shares plunged 80% Monday morning.

Chris Lange | Apr 27, 2015 at 8:30 AM EDT

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Apr 24, 2015 at 9:45 AM EDT

Will Biogen Earnings Interrupt the Biotech Bull Market?

Biogen reported disappointing first-quarter financials before the markets opened Friday.

Jon C. Ogg | Apr 24, 2015 at 7:40 AM EDT

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

A late day call on Thursday from Bank of America Merrill Lynch took GW Pharmaceuticals' share price target far higher.

Paul Ausick | Apr 21, 2015 at 4:29 PM EDT

Amgen Earnings Point to More Froth in the Biotech Sector

Amgen reported better-than-expected first-quarter 2015 earnings Tuesday afternoon after equity markets had closed.

Paul Ausick | Apr 21, 2015 at 11:35 AM EDT

Will Amgen Earnings Shape Biotech for the Rest of 2015?

After markets close on Tuesday, Amgen, the second-largest biotech, is scheduled to announce its first-quarter results.

Chris Lange | Apr 21, 2015 at 11:25 AM EDT

Can La Jolla Pharma Shares Really Double?

La Jolla Pharmaceutical has received an analyst call that implies a potential doubling of its shares.

Chris Lange | Apr 21, 2015 at 9:50 AM EDT

Why Teva Really Wants to Acquire Mylan

Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and…

Chris Lange | Apr 20, 2015 at 4:11 PM EDT

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals may be very misunderstood for what it is.

Chris Lange | Apr 20, 2015 at 3:18 PM EDT

Genetic Technologies Drives Ahead in the Fight Against Cancer

ThinkstockGenetic Technologies Limited (NASDAQ: GENE) has been making large strides in the area of women’s health recently with the opening…

Chris Lange | Apr 20, 2015 at 1:15 PM EDT

Is Ampio at Risk of Imploding?

Ampio announced Monday that a Phase 3 for the treatment pain due to osteoarthritis of the knee did not reach…

Jon C. Ogg | Apr 20, 2015 at 11:30 AM EDT

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

GW Pharmaceuticals shares were actually unexciting on Monday, National Weed Day.

1 … 264 265 266 267 268 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Pfizer Dodges a Bullet on Earnings

What to Expect From Merck and Pfizer Earnings

Key Analyst Sees Nearly 30% Upside in Ironwood

A Real Heartbreak for Celladon

Short Sellers Become More Wary of Big Biotech

Will Biogen Earnings Interrupt the Biotech Bull Market?

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

Amgen Earnings Point to More Froth in the Biotech Sector

Will Amgen Earnings Shape Biotech for the Rest of 2015?

Can La Jolla Pharma Shares Really Double?

Why Teva Really Wants to Acquire Mylan

BioCryst Upgrade Almost Looks Misunderstood

Genetic Technologies Drives Ahead in the Fight Against Cancer

Is Ampio at Risk of Imploding?

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Health and Healthcare Articles

All Health and Healthcare Articles

Pfizer Dodges a Bullet on Earnings

What to Expect From Merck and Pfizer Earnings

Key Analyst Sees Nearly 30% Upside in Ironwood

A Real Heartbreak for Celladon

Short Sellers Become More Wary of Big Biotech

Will Biogen Earnings Interrupt the Biotech Bull Market?

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

Amgen Earnings Point to More Froth in the Biotech Sector

Will Amgen Earnings Shape Biotech for the Rest of 2015?

Can La Jolla Pharma Shares Really Double?

Why Teva Really Wants to Acquire Mylan

BioCryst Upgrade Almost Looks Misunderstood

Genetic Technologies Drives Ahead in the Fight Against Cancer

Is Ampio at Risk of Imploding?

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later